NEW YORK, NY / ACCESSWIRE / August 14, 2017 / Aeterna Zentaris was a big winner on Friday despite posting a loss in its second quarter results. Trader confidence may have been a result of one analyst giving the stock a $4.00 price target on Friday. Shares of EnteroMedics also saw big losses after announcing last Thursday that it has begun an underwritten public offering.
RDI Initiates Coverage on:
Aeterna Zentaris Inc.
Aeterna Zentaris Inc.'s shares closed up 17.92% on Friday on nearly 4.5 million shares traded. Despite a loss in its second quarter, the stock still soared to close in the green. The Montreal biotech company reported a loss of 18 cents per share. After being adjusted for non-recurring gains, the losses were 46 cents per share. This was no reason for such a gain, so why did shares skyrocket? It could it be the hefty price targets on the stock by some analysts. Maxim Group has put a $4.00 price target on the stock and issued a "buy" rating on Friday. Hitting the firm's price target would be upside of over 95% compared to current levels.
Addressing the Company's future plans in its earning statement, CEO Michael V. Ward stated, "We are continuing our commercial organization and infrastructure preparation for the earliest possible launch of Macrilen™ in the United States. Our goal is to be prepared to launch the product in the first quarter of 2018. We are also reviewing our resources and making adjustments consistent with our focus on commercializing Macrilen™. Macrilen is the company's treatment for growth hormone deficiency in adults". Shares blew up in July after the company announced that the Food and Drug Administration accepted the new drug application (NDA) seeking approval of Macrilen as a "complete response." The FDA granted a Prescription Drug User Fee Act (PDUFA) date of Dec. 30.
Access RDI's Aeterna Zentaris Inc. Research Report at:
EnteroMedics Inc.'s shares collapsed on Friday, closing down nearly 40%. The developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders recently reported second quarter financial results. For the period which ended June 30th, 2017, EnteroMedics placed 42 units. This was an increase of 83% compared to just 23 units in the year ago quarter. Sales were $93,000 with gross profit of $39,000. On Thursday the company announced that it has commenced an underwritten public offering. The offering is expected to consist of units comprised of one share of series B convertible preferred stock and one warrant to purchase shares of common stock. According to the company's press release, EnteroMedics intends to use the net proceeds from the offering to continue its commercialization efforts, for clinical and product development activities and for other working capital and general corporate purposes.
Access RDI's EnteroMedics Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.